Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company that recently received approval for its first product, lifileucel, which is commercialized as Amtagvi for melanoma treatment. The company continues to study lifileucel for various cancer indications. Amtagvi is a TIL treatment that reinvigorates the body’s natural cancer-fighting cells. While not yet profitable, Iovance saw a 13% revenue increase to $68 million in the latest quarter. A recent study showed Amtagvi’s strong performance with a 52% objective response rate, higher than in clinical trials. Consider investing in Iovance as lifileucel progresses through studies for potential growth.

Read more at NASDAQ.: 1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits